Company intelligence
Biocytogen
Your Partner From Targets To Therapeutics
About Biocytogen
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.
Verified activity
Signals from Biocytogen
18 published signals
Presence & Recognition
Biocytogen and KACTUS are hosting a Gene-ius Break event on Thursday, September 24 at District Brew Yards in Chicago.
Reported by Biocytogen
Presence & Recognition
Biocytogen is attending the 11th Annual CAR-TCR Summit in Boston from September 15 to 17, 2026.
Reported by Biocytogen
Research & Knowledge
Biocytogen validated its CRBN humanized mice (B-hCRBN mice) as a platform for evaluating CRBN-dependent protein degradation, pharmacodynamic responses, and safety.
Reported by Biocytogen
Products & Services
Biocytogen is building a global platform for antibody discovery and drug development.
Reported by Fengqian Chen, Ph.D.
Research & Knowledge
Biocytogen published a new study in the Journal of Controlled Release introducing AODC, an antibody-oligonucleotide-drug conjugate approach.
Reported by Fengqian Chen, Ph.D.
Presence & Recognition
Biocytogen participated in a first workout at Life Time Burlington in Boston.
Reported by Fengqian Chen, Ph.D.
People
Biocytogen welcomed Fengqian Chen to Boston as a new employee.
Reported by Fengqian Chen, Ph.D.
Research & Knowledge
Biocytogen published a new Nature Biotechnology study reporting AIntibody, a prospective, blinded benchmark testing 511 AI-designed or AI-selected antibodies from 29 organizations with every submission experimentally evaluated for affinity and developability.
Reported by Fengqian Chen, Ph.D.
Presence & Recognition
Biocytogen is attending the Oncology & Immunology Innovation Partnering & Licensing Summit in Boston from September 9 to 10, 2026.
Reported by Biocytogen
Research & Knowledge
Biocytogen published a new study in Nature Communications introducing a bispecific chimeric autoantibody receptor (CAAR)-T strategy for acetylcholine receptor-positive myasthenia gravis.
Reported by Fengqian Chen, Ph.D.
Presence & Recognition
Biocytogen is attending Nordic Life Science Days 2026 in Sweden from September 8 to 9, 2026 at Kistamässan, Arne Beurlings Torg 5, 164 40 Kista, Sweden.
Reported by Biocytogen
Research & Knowledge
Biocytogen published a blog exploring how its target-humanized and disease-relevant mouse models support in vivo evaluation of human target biology, renal pathology, and therapeutic response across emerging areas such as kidney disease, IgAN, complement-mediated disease, ADPKD, and APOL1-mediated disease.
Reported by Biocytogen
Presence & Recognition
Biocytogen is hosting a live webinar on September 23, 2026, featuring speakers Yanan Guo and Zhongxiao Cong to explore integrating RenNano-derived VHHs with target-humanized, immune-reconstituted, and tumor models for CAR-T development.
Reported by Biocytogen
Partnerships
Biocytogen Pharmaceuticals entered into a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule to support innovative drug development in neuroscience.
Reported by Biocytogen
Presence & Recognition
Biocytogen is hosting the Biocytogen Founders Breakfast at Cure in NYC on Wednesday, September 16, 9:00–11:00 AM.
Reported by Deyao Li
Research & Knowledge
Biocytogen published a research paper by the Penn/Carl June team tracking early CD19 CAR-T recipients with B-cell lymphoma and finding CAR transgenes persisting in some responders for 7 to 10 years.
Reported by Fengqian Chen, Ph.D.
Partnerships
Biocytogen announced that RenNano VHH programs are moving forward in neuroscience with Qilu Pharmaceutical.
Reported by Icy Niu
Research & Knowledge
Biocytogen published a new study in Nature Cardiovascular Research using an anti-TREM2 antibody–siRNA conjugate to selectively silence Spp1/osteopontin in a pathogenic subset of cardiac macrophages linked to atrial fibrillation.
Reported by Fengqian Chen, Ph.D.